AxTRAORDINARY: testing targeted therapies for youth with axial spondyloarthritis
Official title: Axial TReatment Agent Options; Responsiveness of Disease to Inhibition of Numerous Anti-Rheumatic pathways in Youth (AxTRAORDINARY)
Funded at Children's Hosp of Philadelphia · NIH-11448749 · Data updated 2026-11-12
A study in children and adults with axial spondyloarthritis will explore a newer oral therapy (a JAK-STAT inhibitor) to find better, more personalized treatments beyond current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 23, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $453,545 |
| NIH project number | 1UG3AR087109-01A1 |
| Project ID | NIH-11448749 on NIH RePORTER |
Who could benefit from this research
✓Could help
Youth and young adults with axial spondyloarthritis or related juvenile arthritis who have axial involvement and have not achieved remission with current therapies.
✕Less likely to help
Patients unlikely to respond to JAK-STAT inhibitors or with contraindications to study drugs may not benefit.
What this research studies
This project focuses on axial spondyloarthritis in youth, a painful and disabling form of juvenile arthritis that often continues into adulthood. It will compare an oral JAK-STAT inhibitor to the standard TNF inhibitor approach, aiming to identify who responds best and why. Researchers will collect immunologic profiles and clinical outcomes to guide future personalized treatment choices. The trial design seeks to reduce trial-and-error prescribing and improve remission rates and quality of life for affected youths and young adults.
Why it matters
Potential benefit: If successful, patients could receive more effective, tailored therapies sooner, reducing pain and disability.
How similar studies have gone: Adult axSpA trials suggest efficacy of JAK-STAT inhibitors, but data in pediatric populations are limited and this study aims to fill that gap.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Weiss, Pamela Fitch — Children's Hosp of Philadelphia
- Study coordinator: Weiss, Pamela Fitch
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.